recombinant human chorionic gonadotropin beta (FE 999302) / Ferring - LARVOL DELTA

Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov) - P1 | N=310 | Terminated | Sponsor: Ferring Pharmaceuticals | N=600 ➔ 310 | Trial completion date: Sep 2026 ➔ Sep 2025 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2026 ➔ Sep 2025; This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Celestial-2: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation. (clinicaltrials.gov) - P1 | N=106 | Terminated | Sponsor: Ferring Pharmaceuticals | N=200 ➔ 106 | Trial completion date: Jul 2026 ➔ Sep 2025 | Recruiting ➔ Terminated | Trial primary completion date: May 2026 ➔ Sep 2025; This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infertility • Sexual Disorders

Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov) - P1 | N=600 | Recruiting | Sponsor: Ferring Pharmaceuticals | Trial completion date: Sep 2027 ➔ Sep 2026

Trial completion date

Celestial-2: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation. (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Ferring Pharmaceuticals

New P1 trial • Infertility • Sexual Disorders

Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov) - P1 | N=600 | Recruiting | Sponsor: Ferring Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open

Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov) - P1 | N=600 | Not yet recruiting | Sponsor: Ferring Pharmaceuticals

New P1 trial

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Ferring Pharmaceuticals | N=500 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Infertility • Sexual Disorders

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=500 | Suspended | Sponsor: Ferring Pharmaceuticals | Recruiting ➔ Suspended

Trial suspension • Infertility • Sexual Disorders

Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosing. (PubMed, Front Endocrinol (Lausanne)) - P2 | "This study is part of a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of CG beta plus recombinant follicle-stimulating hormone (rFSH) in women undergoing OS during a long gonadotrophin-releasing hormone agonist protocol...17-OH-progesterone, androstenedione, testosterone, and estradiol concentrations significantly increased in a CG-beta dose-dependent manner during OS (p<0.0001), reaching up to 10 times higher values in the highest dose group versus placebo...13 June 2018. Presented at the 38th Annual Meeting of the European Society of Human Reproduction and Embryology, P-567, 2022."

Clinical • Journal • AR • CGB • CYP19A1

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=500 | Recruiting | Sponsor: Ferring Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=500 | Not yet recruiting | Sponsor: Ferring Pharmaceuticals

New P2 trial • Infertility • Sexual Disorders